Search alternatives:
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), i non (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), i non (Expand Search)
-
19861
-
19862
Age at treatment initiation–cross sex hormones.
Published 2023“…Puberty suppression (PS) was generally induced with Gonadotropin Releasing Hormone analogues (GnRHa), and at a pooled mean age of 14.5 (±1.0) years. Cross Sex Hormone (CSH) therapy was initiated at a pooled mean of 16.2 (±1.0) years. …”
-
19863
Study characteristics.
Published 2023“…Puberty suppression (PS) was generally induced with Gonadotropin Releasing Hormone analogues (GnRHa), and at a pooled mean age of 14.5 (±1.0) years. Cross Sex Hormone (CSH) therapy was initiated at a pooled mean of 16.2 (±1.0) years. …”
-
19864
Age at treatment initiation–puberty suppression.
Published 2023“…Puberty suppression (PS) was generally induced with Gonadotropin Releasing Hormone analogues (GnRHa), and at a pooled mean age of 14.5 (±1.0) years. Cross Sex Hormone (CSH) therapy was initiated at a pooled mean of 16.2 (±1.0) years. …”
-
19865
Search terms.
Published 2023“…Puberty suppression (PS) was generally induced with Gonadotropin Releasing Hormone analogues (GnRHa), and at a pooled mean age of 14.5 (±1.0) years. Cross Sex Hormone (CSH) therapy was initiated at a pooled mean of 16.2 (±1.0) years. …”
-
19866
PRISMA diagram.
Published 2023“…Puberty suppression (PS) was generally induced with Gonadotropin Releasing Hormone analogues (GnRHa), and at a pooled mean age of 14.5 (±1.0) years. Cross Sex Hormone (CSH) therapy was initiated at a pooled mean of 16.2 (±1.0) years. …”
-
19867
PRISMA 2020 checklist.
Published 2023“…Puberty suppression (PS) was generally induced with Gonadotropin Releasing Hormone analogues (GnRHa), and at a pooled mean age of 14.5 (±1.0) years. Cross Sex Hormone (CSH) therapy was initiated at a pooled mean of 16.2 (±1.0) years. …”
-
19868
-
19869
-
19870
Importance of CD200 expression by tumor or host cells to regulation of immunotherapy in a mouse breast cancer model - Fig 5
Published 2017“…<p>A. WT, CD200<sup>-/-</sup>, and CD200R<sup>-/-</sup> BALB/c mice received 5x10<sup>5</sup> EMT6 tumor cells injected into the mammary fat pad. 15 days later tumors were surgically resected and mice were immunized with irradiated EMT6 cells and CpG as adjuvant [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0171586#pone.0171586.ref004" target="_blank">4</a>]. …”
-
19871
-
19872
-
19873
-
19874
-
19875
-
19876
-
19877
-
19878
Table_5_PpSAUR5 promotes plant growth by regulating lignin and hormone pathways.xls
Published 2024“…Future studies can use PpSAUR5 as a candidate gene to elucidate the potential regulatory mechanisms underlying peach tree vigor.…”
-
19879
-
19880